Development of a smooth muscle-targeted cre recombinase mouse reveals novel insights regarding smooth muscle myosin heavy chain promoter regulation

Circulation Research

Volumn 87, Issue 5, 2000, Pages 363-369

  Regan, Christopher P ^a,b   Manabe, Ichiro ^a   Owens, Gary K ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

Author keywords

Cardiovascular development; Cre recombinase; Gene targeting; Smooth muscle myosin heavy chain; Vascular biology

Indexed keywords

MYOSIN HEAVY CHAIN; RECOMBINASE;

ARTICLE; CARDIOVASCULAR SYSTEM; DEVELOPMENT; EMBRYO; GENE ACTIVATION; GENE CONTROL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SMOOTH MUSCLE; TRANSGENIC MOUSE;

EID: 0034283056     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.87.5.363     Document Type: Article

References (31)

1. Control of mouse cardiac morphogenesis and myogenesis by transcription factor MEF2C
2. Regulation of cardiac mesodermal and neural crest development by the bHLH transcription factor, dHAND
3. The bHLH factors, dHAND and eHAND, specify pulmonary and systemic cardiac ventricles independent of left-right sidedness
4. The basic helix-loop-helix transcription factor, dHAND, is required for vascular development
5. The transcription factor MEF2C-null mouse exhibits complex vascular malformations and reduced cardiac expression of angiopoietin 1 and VEGF
6. Requirement of the MADS-box transcription factor MEF2C for vascular development
7. Lens-specific expression of transforming growth factor β1 in transgenic mice causes anterior subcapsular cataracts
8. Knockout mice: Round two
9. The cardiac homeobox gene Csx/Nkx2.5 lies genetically upstream of multiple genes essential for heart development
10. Targeted oncogene activation by site-specific recombination in transgenic mice
11. A post-transcriptional compensatory pathway in heterozygous ventricular myosin light chain 2-deficient mice results in lack of gene dosage effect during normal cardiac growth or hypertrophy
12. Enhancement of murine cardiac chronotropy by the molecular transfer of the human β2 adrenergic receptor cDNA
13. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress
14. Regulation of smooth muscle α-actin expression in vivo is dependent on CArG elements within the 5' and first intron promoter regions
15. Expression of the SM22α promoter in transgenic mice provides evidence for distinct transcriptional regulatory programs in vascular and visceral smooth muscle cells
16. Regulation of differentiation of vascular smooth muscle cells
17. Smooth muscle myosin heavy chain exclusively marks the smooth muscle lineage during mouse embryogenesis
18. Smooth muscle-specific expression of the smooth muscle myosin heavy chain gene in transgenic mice requires 5' -flanking and first intronic DNA sequence
19. Myosin gene expression and cell phenotypes in vascular smooth muscle during development, in experimental models, and in vascular disease
20. Smooth muscle cell origin and its relation to heterogeneity in development and disease
21. Generalized lacZ expression with the ROSA26 Cre reporter strain
22. Disruption of overlapping transcripts in the ROSA β geo 26 gene trap strain leads to widespread expression of β-galactosidase in mouse embryos and hematopoietic cells
23. Promoter traps in embryonic stem cells: A genetic screen to identify and mutate developmental genes in mice
24. Integration and stable germ line transmission of genes injected into mouse pronuclei
25. Fate of the mammalian cardiac neural crest
26. Using Flp-recombinase to characterize expansion of Wnt1-expressing neural progenitors in the mouse
27. SM22 α, a marker of adult smooth muscle, is expressed in multiple myogenic lineages during embryogenesis
28. Molecular analysis of smooth muscle development in the mouse
29. Fashioning the vertebrate heart: Earliest embryonic decisions
30. Developmental biology of the vascular smooth muscle cell: Building a multilayered vessel wall
31. Conditional gene targeting